AU2016323017B2 - T cell receptors recognizing HLA-Cw8 restricted mutated KRAS - Google Patents

T cell receptors recognizing HLA-Cw8 restricted mutated KRAS Download PDF

Info

Publication number
AU2016323017B2
AU2016323017B2 AU2016323017A AU2016323017A AU2016323017B2 AU 2016323017 B2 AU2016323017 B2 AU 2016323017B2 AU 2016323017 A AU2016323017 A AU 2016323017A AU 2016323017 A AU2016323017 A AU 2016323017A AU 2016323017 B2 AU2016323017 B2 AU 2016323017B2
Authority
AU
Australia
Prior art keywords
seq
leu
val
ser
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016323017A
Other languages
English (en)
Other versions
AU2016323017A1 (en
Inventor
Yong-Chen LU
Steven A. Rosenberg
Eric TRAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of AU2016323017A1 publication Critical patent/AU2016323017A1/en
Application granted granted Critical
Publication of AU2016323017B2 publication Critical patent/AU2016323017B2/en
Priority to AU2021200833A priority Critical patent/AU2021200833B2/en
Priority to AU2022209229A priority patent/AU2022209229B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
    • G01N33/57575—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/82—Translation products from oncogenes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Plant Pathology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
AU2016323017A 2015-09-15 2016-09-09 T cell receptors recognizing HLA-Cw8 restricted mutated KRAS Active AU2016323017B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2021200833A AU2021200833B2 (en) 2015-09-15 2021-02-10 T Cell receptors recognizing HLA-Cw8 restricted mutated KRAS
AU2022209229A AU2022209229B2 (en) 2015-09-15 2022-07-26 T Cell receptors recognizing HLA-Cw8 restricted mutated KRAS

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562218688P 2015-09-15 2015-09-15
US62/218,688 2015-09-15
PCT/US2016/050875 WO2017048593A1 (en) 2015-09-15 2016-09-09 T cell receptors recognizing hla-cw8 restricted mutated kras

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021200833A Division AU2021200833B2 (en) 2015-09-15 2021-02-10 T Cell receptors recognizing HLA-Cw8 restricted mutated KRAS

Publications (2)

Publication Number Publication Date
AU2016323017A1 AU2016323017A1 (en) 2018-04-05
AU2016323017B2 true AU2016323017B2 (en) 2020-11-12

Family

ID=56985686

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016323017A Active AU2016323017B2 (en) 2015-09-15 2016-09-09 T cell receptors recognizing HLA-Cw8 restricted mutated KRAS
AU2021200833A Active AU2021200833B2 (en) 2015-09-15 2021-02-10 T Cell receptors recognizing HLA-Cw8 restricted mutated KRAS
AU2022209229A Active AU2022209229B2 (en) 2015-09-15 2022-07-26 T Cell receptors recognizing HLA-Cw8 restricted mutated KRAS

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2021200833A Active AU2021200833B2 (en) 2015-09-15 2021-02-10 T Cell receptors recognizing HLA-Cw8 restricted mutated KRAS
AU2022209229A Active AU2022209229B2 (en) 2015-09-15 2022-07-26 T Cell receptors recognizing HLA-Cw8 restricted mutated KRAS

Country Status (13)

Country Link
US (3) US10556940B2 (enExample)
EP (2) EP3901169A1 (enExample)
JP (2) JP7185524B2 (enExample)
KR (2) KR102841067B1 (enExample)
CN (2) CN115073583A (enExample)
AU (3) AU2016323017B2 (enExample)
DK (1) DK3350213T3 (enExample)
ES (1) ES2879287T3 (enExample)
IL (1) IL257840B2 (enExample)
MX (1) MX2018003062A (enExample)
SA (1) SA518391109B1 (enExample)
SG (1) SG10201913868XA (enExample)
WO (1) WO2017048593A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2993431A1 (en) 2015-07-31 2017-02-09 Regents Of The University Of Minnesota Nuclease based knockouts of immunological checkpoint genes in immune cells
CN109790211B (zh) * 2016-08-02 2024-03-26 美国卫生和人力服务部 抗kras-g12d t细胞受体
GB201700621D0 (en) 2017-01-13 2017-03-01 Guest Ryan Dominic Method,device and kit for the aseptic isolation,enrichment and stabilsation of cells from mammalian solid tissue
EP4234576A3 (en) * 2017-03-31 2023-09-13 The United States of America, as represented by the Secretary, Department of Health and Human Services Methods of isolating neoantigen-specific t cell receptor sequences
JP7381345B2 (ja) * 2017-05-16 2023-11-15 ザ・ジョンズ・ホプキンス・ユニバーシティ Ｍａｎａボディおよび使用方法
EP3645021A4 (en) 2017-06-30 2021-04-21 Intima Bioscience, Inc. ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
US11306132B2 (en) * 2017-09-20 2022-04-19 The United States Of America, As Represented By The Secretary Department Of Health And Human Services HLA class II-restricted T cell receptors against mutated RAS
MA50748A (fr) 2017-10-05 2020-08-12 Us Health Méthodes d'expansion sélective de cellules exprimant un tcr avec une région constante murine
CN119162251A (zh) 2017-12-04 2024-12-20 美国卫生和人力服务部 针对突变的ras的hla i类限制性t细胞受体
TW202015719A (zh) * 2018-06-19 2020-05-01 美商尼恩醫療公司 新抗原及其用途
WO2020037239A1 (en) * 2018-08-16 2020-02-20 Neon Therapeutics, Inc. T cell receptor constructs and uses thereof
JP7672979B2 (ja) * 2019-01-22 2025-05-08 アメリカ合衆国 Ｇ１２ｒ変異を有するｒａｓに対するｈｌａクラスｉｉ拘束性ｔ細胞受容体
CA3130618A1 (en) 2019-02-20 2020-08-27 Fred Hutchinson Cancer Research Center Binding proteins specific for ras neoantigens and uses thereof
US20220175899A1 (en) * 2019-04-11 2022-06-09 The Board Of Trustees Of The Leland Stanford Junior University Cytotoxic t lymphocytes specific for mutated forms of epidermal growth factor receptor for use in treating cancer
CN110172089B (zh) * 2019-06-11 2020-01-07 北京鼎成肽源生物技术有限公司 一种kras突变多抗原组合、靶向kras突变肿瘤ctl及其应用
CN112110995A (zh) * 2019-06-19 2020-12-22 上海交通大学医学院 肿瘤新抗原多肽及其用途
WO2021029046A1 (ja) * 2019-08-14 2021-02-18 日本電気株式会社 情報処理装置、情報処理方法及び記録媒体
CN112759641B (zh) * 2019-11-01 2023-01-20 香雪生命科学技术（广东）有限公司 一种识别Kras G12V的高亲和力TCR
BR112022011795A2 (pt) 2019-12-20 2022-08-30 Instil Bio Uk Ltd Métodos para preparar e isolar uma população terapêutica de linfócitos e para tratar câncer em um indivíduo, população terapêutica de linfócitos, bolsa criopreservada, recipiente flexível, e, sistema para extração de linfócitos
EP4103598A1 (en) * 2020-02-14 2022-12-21 The United States of America, as represented by the Secretary, Department of Health and Human Services Hla class i-restricted t cell receptors against ras with g12v mutation
CN111574616B (zh) * 2020-06-17 2021-02-02 深圳豪石生物科技有限公司 分离的t细胞受体和应用
AU2021309958A1 (en) * 2020-07-16 2023-02-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HLA class II-restricted DRB T cell receptors against RAS with G12V mutation
WO2022072760A1 (en) * 2020-10-02 2022-04-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Hla class ii-restricted dq t cell receptors against ras with g13d mutation
IL305393A (en) 2021-02-25 2023-10-01 Alaunos Therapeutics Inc Recombinant vectors comprising polycistronic expression cassettes and methods of use thereof
WO2023150562A1 (en) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Methods for activation and expansion of t cells
CN114920824B (zh) * 2022-05-27 2023-12-05 重庆医科大学 Tcr或其抗原结合片段及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7301017B2 (en) * 2002-05-30 2007-11-27 Kolesnick Richard N Kinase suppressor of Ras inactivation for therapy of Ras mediated tumorigenesis
WO2004021995A2 (en) 2002-09-06 2004-03-18 The Government Of The United States Of America, Represented By The Secretary, Departement Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
ES2672895T3 (es) * 2005-08-05 2018-06-18 Helmholtz Zentrum München Deutsches Forschungszentrum Für Gesundheit Und Umwelt Gmbh Generación de células T específicas de antígeno
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
CA2812153C (en) * 2010-09-20 2020-06-30 Biontech Ag Antigen-specific t cell receptors and t cell epitopes
WO2012129201A1 (en) 2011-03-22 2012-09-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
AU2012309830B2 (en) * 2011-09-15 2017-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing HLA-A1- or HLA-Cw7-restricted mage
GB201314404D0 (en) * 2013-08-12 2013-09-25 Immunocore Ltd T Cell Receptors
CN118994363A (zh) 2014-11-26 2024-11-22 美国卫生和人力服务部 抗突变的kras的t细胞受体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
FREDERICK D. TSAI ET AL, "K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 112, no. 3, pages 779 - 784 *

Also Published As

Publication number Publication date
WO2017048593A1 (en) 2017-03-23
DK3350213T3 (da) 2021-06-21
IL257840A (en) 2018-04-30
US11667692B2 (en) 2023-06-06
EP3350213B1 (en) 2021-03-31
JP7461445B2 (ja) 2024-04-03
AU2016323017A1 (en) 2018-04-05
US20230406904A1 (en) 2023-12-21
ES2879287T3 (es) 2021-11-22
HK1257902A1 (en) 2019-11-01
US20190040111A1 (en) 2019-02-07
CN108350059B (zh) 2021-10-08
KR20250117744A (ko) 2025-08-05
AU2021200833A1 (en) 2021-03-04
AU2022209229A1 (en) 2022-09-15
US20200148739A1 (en) 2020-05-14
SG10201913868XA (en) 2020-03-30
AU2022209229B2 (en) 2024-05-23
CN108350059A (zh) 2018-07-31
US10556940B2 (en) 2020-02-11
KR20180044428A (ko) 2018-05-02
IL257840B2 (en) 2023-10-01
CN115073583A (zh) 2022-09-20
IL257840B1 (en) 2023-06-01
SA518391109B1 (ar) 2022-02-14
EP3350213A1 (en) 2018-07-25
CA2998869A1 (en) 2017-03-23
JP2023025108A (ja) 2023-02-21
JP2018535647A (ja) 2018-12-06
MX2018003062A (es) 2018-09-11
KR102841067B1 (ko) 2025-08-01
AU2021200833B2 (en) 2022-04-28
EP3901169A1 (en) 2021-10-27
JP7185524B2 (ja) 2022-12-07

Similar Documents

Publication Publication Date Title
AU2021200833B2 (en) T Cell receptors recognizing HLA-Cw8 restricted mutated KRAS
US12391742B2 (en) Anti-KRAS-G12D T cell receptors
CA3021898A1 (en) Anti-kk-lc-1 t cell receptors
CA2998869C (en) T cell receptors recognizing hla-cw8 restricted mutated kras
HK1257902B (en) T cell receptors recognizing hla-cw8 restricted mutated kras
EP4326751A1 (en) Hla class i-restricted t cell receptors against ras with q61k mutation

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)